The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis

Pediatric Allergy and Immunology

Volumn 17, Issue 6, 2006, Pages 396-407

  Keskin, Özlem ^a   Tuncer, Ayfer ^a   Adalioglu, Gonul ^a   Sekerel, Bulent E ^a   Saçkesen, Cansin ^a   Kalayci, Omer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Allergic rhinitis; Allergoid immunotherapy; Bronchial reactivity; Children; Eosinophil cationic protein; Grass; Interleukin 4

Indexed keywords

ALLERGOVIT; ANTIHISTAMINIC AGENT; BUDESONIDE; DECONGESTIVE AGENT; EOSINOPHIL CATIONIC PROTEIN; GRASS POLLEN ALLERGOID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INTERLEUKIN 4; LORATADINE; OLOPATADINE; OXYMETAZOLINE; POLLEN ANTIGEN; STEROID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ALLERGOID IMUNOTHERAPY; ARTICLE; BRONCHUS HYPERREACTIVITY; CELL CULTURE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DACTYLIS; DRUG SAFETY; EOSINOPHIL; FEMALE; FESCUE; HOLCUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MAINTENANCE THERAPY; MALE; NOSE MUCUS; PARAMETER; PERENNIAL RYEGRASS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHLEUM PRATENSE; POA; POLLEN ALLERGY; PRIORITY JOURNAL; PROVOCATION TEST; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SKIN TEST; SUPERNATANT; SYMPTOM;

ADOLESCENT; ALLERGENS; BRONCHIAL HYPERREACTIVITY; CHILD; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MALE; NASAL LAVAGE FLUID; NASAL PROVOCATION TESTS; PLANT EXTRACTS; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL;

EID: 33747887028     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2006.00442.x     Document Type: Article

References (34)

1. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N (WHO); and the Workshop Expert Panel Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland. Allergy 2002: 57: 841-55.
2. BOUSQUET J, LOCKEY R, MALLING HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998: 102: 558-62.
3. WALKER SM, PAJNO GB, LIMA MT, WILSON DR, DURHAM SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001: 107: 87-93.
4. CORRIGAN CJ FOR THE STUDY GROUP, KETTNER J, DOEMER C, CROMWELL O, NARKUS A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005: 60: 801-7.
5. KLIMEK L, DORMANN D, JARMAN ER, CROMWELL O, RIECHELMANN H, RESKE-KUNZ AB. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999: 29: 1326-35.
6. ARIANO R, KROON AM, AUGERI G, CANONICA GW, PASSALACQUA G. Long term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 1999: 54: 313-9.
7. MÖLLER C, DREBORG S, FERDOUSI HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002: 109: 251-6.
8. VAN METRE TE, ADKINSON NF JR, AMODIO FJ, et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980: 66: 500-13.
9. GARDNER LM, SPYROGLOU L, O'HEHIR RE, ROLLAND RM. Increased allergen concentration enhances IFN-γ production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. Allergy 2004: 59: 1308-17.
10. PASSALACQUA G, CANONICA GW. Alternative routes for immunotherapy. J Invest Allergol Clin Immunol 1996: 6: 81-6.
11. CASANOVAS M, FERNÁNDEZ-CALDAS E, ALAMAR R, BASOMBA A. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2005: 137: 211-8
12. NORMAN PS, LICHTENSTEIN LM, KAGEY-SOBOTKA A, MARSH DG. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever. J Allergy Clin Immunol 1982: 70: 248-60.
13. PASTARELLO EA, PRAVETTONI V, INCORVAIA C, et al. Clinical and immunological effects of immunotherapy with aluminium-absorbed grass allergoid in grass pollen-induced hay fever. Allergy 1992: 47: 281-90.
14. BOUSQUET J, HEJJAOUI A, SOUSSANA M, MICHEL FB. Double-blind, placebo-controlled immunotherapy with mixed grass pollen allergoids. IV. Comparison of the efficacy and safety of two dosages of a high molecular weight allergoid. J Allergy Clin Immunol 1990: 85: 490-7.
15. DURHAM SR, TILL SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998: 102: 157-64.
16. WILSON DR, IRANI A-MA, WALKER SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001: 31: 1705-13.
17. EBNER C, SIEMANN U, BOHLE B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997: 27: 1007-15.
18. + T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003: 111: 1255-61.
19. YANG X, GIENI RS, MOSMANN TR, HAYGLASS KT. Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo. J Exp Med 1993: 178: 349-53.
20. LEBEL B, BOUSQUET J, MOREL A, CHANAL I, GODARD P, MICHEL FB. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol 1988: 82: 869-77.
21. KUNA P, LAZAROVICH M, KAPLAN AP. Chemokines in seasonal allergic rhinitis. J Allergy Clin Immunol 1996: 97: 104-12.
22. IBANEZ SENDIN MD. Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy. Allergol Immunopathol (Madr) 2000: 28: 82-9.
23. ENG PA, REINHOLD M, GNEHM HPE. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002: 57: 306-12.
24. SETTIPANE RJ, HAGY GW, SETTIPANE GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994: 15: 21-5.
25. BRAMAN SS, BARROWS AA, DECOTIIS BA, SETTIPANE GA, CORRAO WM. Airway hyperresponsiveness in allergic rhinitis. A risk factor for asthma. Chest 1987: 91: 671-4.
26. PALMA-CARLOS AG, SPINOLA-SANTOS A, FERREIRA MB, SANTOS MC, PALMA-CARLOS ML. Immunotherapy in allergic rhinitis. Allerg Immunol 2001: 33: 323-6.
27. VAN NEERVEN RJ, WIKBORG T, LUND G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999: 163: 2944-52.
28. WACHHOLZ PA, SONI NK, TILL SJ, DURHAM SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003: 112: 915-22.
29. BOUSQUET J, MAASCH H, MARTINOT B, HEJJAOUI A, WAHL R, MICHEL FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988: 82: 439-46.
30. FU CL, YE YL, LEE YL, CHIANG BL. Both allergen-specific CD4 and CD8 type 2 T cells decreased in asthmatic children with immunotherapy. Pediatr Allergy Immunol 2003: 14: 284-91.
31. JUTEL M, AKDIS M, BLASER K, AKDIS CA. Are regulatory T cells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol 2005: 5: 365-9.
32. SAVOLAINEN J, LAAKSONEN K, RANTIO-LEHTIMAKI A, TERHO EO. Increased expression of allergen-induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy 2004: 34: 413-9.
33. SADEGHI HM, SCHNELLE JF, THOMA JK, NISHANIAN P, FAHEY JL. Phenotypic and functional characteristics of circulating monocytes of elderly persons. Exp Gerontol 1999: 34: 959-70.
34. VOLTOLINI S, MODENA P, MINALE P, et al. Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol 200: 29: 103-10.